Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 54,452 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 54,452 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $1.21, for a total value of $65,886.92. Following the transaction, the insider directly owned 5,904,720 shares in the company, valued at approximately $7,144,711.20. This represents a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Ansbert Gadicke sold 72,709 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Trading Down 1.6%

HOWL traded down $0.02 during trading hours on Thursday, reaching $1.20. 647,728 shares of the company’s stock traded hands, compared to its average volume of 891,846. The firm has a 50-day moving average price of $1.61 and a 200 day moving average price of $1.32. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.41. The company has a quick ratio of 5.30, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $58.25 million, a PE ratio of -0.74 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on HOWL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Bank of America lowered their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 25th. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Finally, JMP Securities lowered their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC raised its position in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. Bank of America Corp DE raised its position in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $409,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $48,000. Finally, Marshall Wace LLP bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $113,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.